VERTEX PHARMACEUTICALS INC / MA Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $20.88 per share for the 12-month period ending 2011-12-31, per its 10-K filed 2012-02-22.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2012-02-22
- VERTEX PHARMACEUTICALS INC / MA share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2011 was $20.88, a 12.74% increase from fiscal 2010.
- VERTEX PHARMACEUTICALS INC / MA share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2010 was $18.52, a 3.09% decline from fiscal 2009.
- VERTEX PHARMACEUTICALS INC / MA share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2009 was $19.11, a 33.36% increase from fiscal 2008.
- VERTEX PHARMACEUTICALS INC / MA share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2008 was $14.33.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|
| 2011-12-31 | $20.88 10-K · filed 2012-02-22 |
| 2010-12-31 | $18.52 10-K · filed 2012-02-22 |
| 2009-12-31 | $19.11 10-K · filed 2012-02-22 |
| 2008-12-31 | $14.33 10-K · filed 2011-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |